Bausch + Lomb Co. (NYSE:BLCO) Receives $15.50 Consensus PT from Analysts

Shares of Bausch + Lomb Co. (NYSE:BLCO) have been assigned a consensus rating of “Hold” from the twelve analysts that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $15.50.

A number of research analysts recently commented on the company. Royal Bank of Canada cut their target price on Bausch + Lomb from $18.00 to $17.00 and set an “outperform” rating for the company in a research note on Friday, April 4th. Wells Fargo & Company cut their target price on Bausch + Lomb from $15.00 to $12.00 and set an “equal weight” rating for the company in a research note on Thursday, May 1st. Evercore ISI cut their target price on Bausch + Lomb from $19.00 to $15.50 and set an “outperform” rating for the company in a research note on Thursday, May 1st. Stifel Nicolaus cut their target price on Bausch + Lomb from $17.00 to $15.00 and set a “hold” rating for the company in a research note on Thursday, April 3rd. Finally, HC Wainwright cut their target price on Bausch + Lomb from $20.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, May 2nd.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of BLCO. Deutsche Bank AG acquired a new stake in shares of Bausch + Lomb in the first quarter valued at $50,750,000. Alberta Investment Management Corp increased its stake in shares of Bausch + Lomb by 8.6% in the first quarter. Alberta Investment Management Corp now owns 3,266,193 shares of the company’s stock valued at $47,360,000 after buying an additional 258,000 shares in the last quarter. Whitebox Advisors LLC increased its stake in shares of Bausch + Lomb by 16.1% in the fourth quarter. Whitebox Advisors LLC now owns 1,443,101 shares of the company’s stock valued at $26,062,000 after buying an additional 199,856 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its stake in shares of Bausch + Lomb by 51.5% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,218,431 shares of the company’s stock valued at $21,996,000 after buying an additional 414,138 shares in the last quarter. Finally, King Street Capital Management L.P. increased its stake in shares of Bausch + Lomb by 55.2% in the fourth quarter. King Street Capital Management L.P. now owns 1,136,321 shares of the company’s stock valued at $20,522,000 after buying an additional 404,256 shares in the last quarter. 11.07% of the stock is currently owned by institutional investors and hedge funds.

Bausch + Lomb Stock Up 5.6%

BLCO opened at $11.91 on Friday. Bausch + Lomb has a 1-year low of $10.45 and a 1-year high of $21.69. The company has a current ratio of 1.60, a quick ratio of 1.01 and a debt-to-equity ratio of 0.72. The stock has a market capitalization of $4.21 billion, a price-to-earnings ratio of -13.08, a P/E/G ratio of 0.85 and a beta of 0.58. The business has a 50 day moving average of $13.37 and a 200-day moving average of $16.48.

Bausch + Lomb (NYSE:BLCO) last posted its quarterly earnings data on Wednesday, April 30th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.10). The business had revenue of $1.15 billion during the quarter, compared to the consensus estimate of $1.15 billion. Bausch + Lomb had a negative net margin of 6.62% and a positive return on equity of 3.35%. The firm’s revenue was up 3.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.07 earnings per share. As a group, sell-side analysts anticipate that Bausch + Lomb will post 0.74 earnings per share for the current year.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.